©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Inhibition of Macrophage Scavenger Receptor Activity by Tumor Necrosis Factor- Is Transcriptionally and Post-transcriptionally Regulated (*)

(Received for publication, November 14, 1995)

Hsien-Yeh Hsu (1)(§) Andrew C. Nicholson (2)(¶) David P. Hajjar (3)(**)

From the  (1)Departments of Medicine, (2)Pathology, and (3)Biochemistry, Cornell University Medical College, New York, New York 10021

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Regulation of expression of the scavenger receptor is thought to play a critical role in the accumulation of lipid by macrophages in atherosclerosis. Tumor necrosis factor-alpha (TNF-alpha) has been shown to suppress macrophage scavenger receptor function (van Lenten, B. J., and Fogelman, A. M.(1992) J. Immunol. 148, 112-116). However, the mechanism by which it does so is unknown. We evaluated the mechanism by which TNF-alpha inhibited macrophage scavenger receptor surface expression and binding of acetylated low density lipoprotein (aLDL). Binding of aLDL to phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages was suppressed by TNF-alpha in a dose-dependent manner. Inhibition of aLDL binding was paralleled by a reduction of macrophage scavenger receptor protein as detected by the Western blot. TNF-alpha partially decreased macrophage scavenger receptor mRNA steady state levels in PMA-differentiated THP-1 macrophages, a result that was confirmed by reverse transcription-polymerase chain reaction. PMA increased the luciferase activity driven by the macrophage scavenger receptor promoter in the transfected cells, whereas TNF-alpha partially reduced luciferase activity. However, macrophage scavenger receptor mRNA half-life was dramatically reduced in cells treated with TNF-alpha relative to untreated cells. Reduction in macrophage scavenger receptor message in response to TNF-alpha was dependent on new protein synthesis because it was blocked by cycloheximide. These results indicate that TNF-alpha regulates macrophage scavenger receptor expression in PMA-differentiated THP-1 macrophages by transcriptional and post-transcriptional mechanisms but principally by destabilization of macrophage scavenger receptor mRNA.


INTRODUCTION

Macrophage scavenger receptors bind oxidized low density lipoprotein (LDL) (^1)and acetylated LDL (aLDL), as well as other polyanionic ligands, and were initially identified by their ability to bind charge modified LDL but not native LDL(2) . Unlike the LDL receptor, expression of the macrophage scavenger receptor is not down-regulated by high levels of intracellular cholesterol. Because of the potential role of this receptor in mediating cholesteryl ester accumulation by macrophages during atherosclerosis, the regulation of expression of these receptors is of considerable important and interest. Circulating monocytes express little or no macrophage scavenger receptor, but receptor mRNA and surface expression are dramatically increased because monocytes differentiate into macrophages in tissue culture. Treatment of monocytes or THP-1 cells (a human monocytic cell line) with phorbol-12 myristate 13-acetate (PMA) also promotes differentiation and induces macrophage scavenger receptor expression(3) . Similarly, macrophage colony-stimulating factor (M-CSF) augments macrophage scavenger receptor expression(4) .

Inhibition of macrophage scavenger receptor expression and activity has been reported in response to interferon- (IFN-)(5, 6) , transforming growth factor-beta1 (TGF-beta1)(7) , all-trans retinoic acid, dexamethasone(8) , platelet secretary products(9, 10, 11) , and lymphocyte culture supernatants(12) . Bacterial lipopolysaccharide (LPS), a potent activator of mononuclear phagocytes, can inhibit scavenger receptor activity in human macrophages(13) . Most of the inhibitory activity of LPS on the macrophage scavenger receptor could be blocked with an antibody to TNF-alpha(1) , suggesting that TNF-alpha, which is synthesized in response to LPS, mediated the LPS effect. However, the molecular mechanism(s) by which TNF-alpha inhibits macrophage scavenger receptor activity have not been elucidated. In this study, we demonstrate that TNF-alpha inhibits macrophage scavenger receptor binding activity, surface protein expression, and mRNA levels, with subsequent down-regulation of macrophage scavenger receptor-mediated ACAT activity and cholesterol esterification in PMA-differentiated THP-1 macrophages. Although macrophage scavenger receptor transcriptional activity was modestly reduced in response to TNF-alpha, in the presence of actinomycin D, macrophage scavenger receptor mRNA half-life was significantly reduced, implying that TNF-alpha inhibits macrophage scavenger receptor expression principally by post-transcriptional decreases in macrophage scavenger receptor mRNA stability.


EXPERIMENTAL PROCEDURES

Materials

Disposable tissue culture materials were purchased from Corning Glass Works (Corning, NY). Medium RPMI 1640 medium, L-glutamine, penicillin, streptomycin, and fetal calf serum were purchased from Life Technologies, Inc. A 100-base pair DNA ladder was purchased from Life Technologies, Inc., MD. I was obtained from ICN Biochemicals (Costa Mesa, CA). EGTA, leupeptin, aprotinin and DNA molecular weight marker V were obtained from Boehringer Mannheim. Sodium orthovanadate was obtained from Aldrich. HEPES, NaCl, glycerol, Triton X-100, MgCl(2), phenylmethylsulfonyl fluoride, PMA, actinomycin D, cycloheximide, and bovine serum albumin (Fraction V) were purchased from Sigma. Immobilon membrane was purchased from Millipore, MA. DuPont Western blot Chemiluminescence Reagent, Renaissance®, a nonradioactive light-emitting system, was purchased from DuPont NEN.

Growth Factors and Antibodies

Human recombinant TNF-alpha and human recombinant M-CSF were obtained from R & D Systems (Minneapolis, MN). Rabbit polyclonal anti-human macrophage scavenger receptor antibody, i.e. hSRI-2 anti-macrophage scavenger receptor peptide antibody, was a gift from Dr. T. Kodama (University of Tokyo, Tokyo, Japan)(14) . Donkey anti-rabbit IgG-horseradish peroxidase conjugate was obtained from Boehringer Mannheim.

Cell Culture

The human monocytic macrophage THP-1 cell line (15, 16) was purchased from ATCC (Rockville, MD) and followed the ATCC protocol to grow. Cells were incubated in 5% CO(2) in air at 37 °C. In this paper, human suspension monocytic THP-1 cell is referred to as THP-1 monocyte; for PMA-differentiated adhesion macrophage-like THP-1 cell is referred to as PMA-differentiated THP-1 macrophage or THP-1 macrophage as described(7, 16, 17, 18) .

Isolation and Labeling of Modified LDL

Human LDL (d = 1.019-1.063 gm/ml) was prepared as described(19) . All LDL preparations were screened for peroxides(20) . LDL was labeled by the method of Bilheimer et al.(21) as described by Goldstein et al.(22) yielding I-aLDL with specific activity between 120 and 220 cpm/ng protein.

Modified LDL Binding

The binding of I-aLDL was performed according to published methods(22) . I-aLDL was added to cells in the presence or the absence of a 100-fold excess of unlabeled aLDL at 4 °C. After 2 h on a rotary shaker, the cells were washed three times with ice-cold phosphate-buffered saline containing 2 mg/ml of bovine serum albumin and then washed two times with ice-cold phosphate-buffered saline. The cells were solubilized in 0.2 M NaOH, and radioactivity was quantified in a Searle 1185 gamma counter (Searle Radiographics, Inc., IL). Nonspecifically bound I-aLDL was determined by incubating cells with a 100-fold excess of unlabeled aLDL. Specific aLDL binding was determined by subtracting nonspecifically bound counts from total counts. Binding was normalized to protein content of the cell layer.

RNA Isolation and Northern Analysis

Total RNA was isolated by the guanidium isothiocyanate method(23) . Northern blot analyses were performed as described(24, 25) . The cDNA for the human macrophage scavenger receptor was a gift from Dr. T. Kodama (University of Tokyo, Tokyo, Japan)(26) . The cDNA for human 28 S ribosomal RNA was a gift from Dr. Iris L. Gonzalez (Hahnemann University, Philadelphia, PA). RNA from Northern blots was quantified using a PhosphorImager® (Molecular Dynamics, Sunnyvale, CA), and normalized by comparison with mRNA of 28 S ribosomal RNA, a constitutively expressed gene.

DEAE-Dextran Sulfate Transfection and Luciferase Assay

-Cells were subpassaged the day before transfection and replaced with fresh medium. The transfection method is described elsewhere(27) . Briefly, the plasmid of macrophage scavenger receptor promoter in luciferase reporter gene, such as plasmids HACLDL Xba-A1-luc promoter and HACLDL Xba-A1-luc Enhancer, respectively (a gift from Dr. C. Glass, University of California, San Diego, CA)(28) , were co-transfected with beta-galactosidase as to monitor the transfection efficiency. Transfected cells were treated with various reagents as indicated, and luciferase activities were measured according to the method previously described(25) . beta-Galactosidase assay was followed the protocol supplied by Promega Co.

Cholesteryl Ester Metabolizing Enzymes

Acid (lysosomal) CE hydrolase activity was assayed at pH 3.9(29) , and, neutral (cytoplasmic) CE hydrolase activity was assayed at pH 7.0(30) . ACAT activity in homogenates was measured as an index of CE synthetic activity by determining the rate of CE synthesis from [1-^14C]oleoyl CoA using exogenous free cholesterol incorporated into unilamellar liposomes containing egg phosphatidylcholine(31) .

Esterification of [^3H]Oleic Acid into Cellular Cholesteryl Ester

THP-1 cells were exposed to a [^3H]oleic acid (sp. act. 40,000 dpm/nmol)/albumin mixture (final concentration, 100 µM oleate, 20 µM albumin in the absence of fetal calf serum) for 24 h at 37 °C. Cell lipids were extracted, and radioactivity in CE was assessed after separation by TLC as described(32) .

Western Blotting Analysis

The method for immunoblotting is described elsewhere(33, 34) . Briefly, THP-1 monocytes treated with PMA (150 nM), or PMA (150 nM) + TNF-alpha (200 units/ml) for 24 h. Whole cell lysates (120 µg of protein) were solubilized in SDS sample buffer with mild reducing conditions (boiling for 5 min in the presence of 2-mercaptoethanol). Protein was loaded in each lane, separated by SDS-polyacrylamide gel electrophoresis, and transferred to an Immobilon membrane. The presence of macrophage scavenger receptor protein was examined by incubation the membrane with hSRI-2 anti-macrophage scavenger receptor peptide antibody (a rabbit polyclonal anti-human macrophage scavenger receptor antibody), which recognizes the collagen-like domain that is shared between types SR-AI and SR-AII macrophage scavenger receptor proteins(14) . Blots were stained with a donkey anti-rabbit IgG-horseradish peroxidase conjugate. Protein visualization was performed with Renaissance®, DuPont Western blot Chemiluminescence Reagent, (DuPont NEN). Manufacturer-provided protocols were followed.

Reverse Transcription Reaction and Polymerase Chain Reaction Amplification for Human Macrophage Scavenger Receptor

The reagents in RNA PCR kit for RT-PCR amplification were purchased from Perkin-Elmer. The oligonucleotides for the primers (26, 35) and the procedures for RT-PCR amplification were as described (35) with some modification. After electrophoresis on 2% agarose gels, the PCR products were stained with ethidium bromide and visualized on a UV transilluminator. Quantitative analysis of PCR products was performed by using Southern blot, and the membranes were hybridized with the P-labeled internal probe as described (35) and quantified using a PhosphorImager®. Differences in intensity of PCR product bands were confirmed by 10-fold serial dilution of cDNA samples to ensure comparability and that the plateau of amplification had not been reached as described(36) .

Protein Assay

Protein amounts were determined by the method of Lowry et al.(37) or the Bio-Rad protein assay.

Statistical Analysis

Statistical differences between the experimental groups were examined by analysis of variance, and statistical significance was determined at a p level of <0.05. All data are expressed as the means ± S.E.


RESULTS

PMA and M-CSF equivalently increased the specific binding (4 °C) of I-aLDL to THP-1 macrophages compared with untreated THP-1 monocytes (Fig. 1A). Co-treatment of PMA- or M-CSF-differentiated THP-1 cells with TNF-alpha reduced specific binding of I-aLDL to baseline (control) levels (Fig. 1A) in a dose-dependent manner (Fig. 2). The effect of TNF-alpha on I-aLDL binding resulted from a decrease in the number of binding sites (B(max)) without significant change in receptor affinity (K(d)). Scatchard analysis (Fig. 1B) demonstrated that PMA or M-CSF increased B(max) by 6- or 7-fold, respectively, as compared with undifferentiated THP-1 monocytes (undifferentiated THP-1 monocytes (control) = 1.66 times 10^5 sites/cell; PMA-differentiated THP-1 macrophages) = 9.71 times 10^5 sites/cell; M-CSF treated THP-1 cells = 10.6 times 10^5 sites/cell). The B(max) of undifferentiated THP-1 monocytes (control), PMA-differentiated THP-1 macrophages treated with TNF-alpha (PMA + TNF-alpha), as well as THP-1 monocytes treated with TNF-alpha and M-CSF-differentiated THP-1 macrophages treated with TNF-alpha, (data not shown) were equivalent (each approximately 1.23-1.66 times 10^5 sites/cell). K(d) values were not significantly altered by any treatment (Fig. 1B).


Figure 1: Effect of TNF-alpha on aLDL-specific binding. A, human THP-1 monocytes were grown to about 1 times 10^6 cells/ml in 12-well plates and then placed in serum-free medium (Control, undifferentiated THP-1 monocytes), serum-free medium with 150 nM PMA (PMA, THP-1 macrophages), serum-free medium with PMA + 200 units/ml TNF-alpha, (PMA + TNF-alpha), or serum-free medium with 3.5 nM M-CSF (M-CSF), as well as serum-free medium with M-CSF + TNF-alpha, or serum-free medium with TNF-alpha alone (data not shown), for 24 h prior to the addition of the indicated concentration of I-aLDL. Binding studies were performed for 2 h at 4 °C as described under ``Experimental Procedures.'' The points represent the mean of triplicate wells ± S.E. and are representative of two separate experiments. B, Scatchard analysis of A.




Figure 2: Dose response effect of TNF-alpha on aLDL binding in PMA-differentiated THP-1 macrophages. PMA-differentiated THP-1 macrophages were incubated with varying concentrations of TNF-alpha (1-300 units/ml). Specific aLDL binding (I-aLDL, 20 µg/ml) was performed as described under ``Experimental Procedures.''



Western analysis (Fig. 3) revealed that little or no macrophage scavenger receptor protein was expressed in THP-1 monocytes. PMA-differentiated THP-1 macrophages expressed scavenger receptor protein, but TNF-alpha suppressed the expression of macrophage scavenger receptor protein when THP-1 cells co-incubated with PMA. TNF-alpha did not cause any signs of general cellular toxicity. Cells treated with PMA/TNF-alpha remained adherent and morphologically similar to PMA-treated cells (THP-1 macrophages). Furthermore, there was no decrease in protein content or cell number or any increase in the uptake of trypan blue (data not shown).


Figure 3: Western blot analysis of MSR protein expression in PMA-differentiated THP-1 macrophages. THP-1 cells were treated as indicated. Lane 1, THP-1 monocytes treated with PMA (150 nM) for 24 h and differentiated into THP-1 macrophages; lane 2, THP-1 monocytes treated with PMA (150 nM) + TNF-alpha (200 units/ml) for 24 h; lane 3, control, undifferentiated THP-1 monocytes. The detailed method is described under ``Experimental Procedures.'' The molecular mass (M.W.; in kDa) standards are indicated on the right side. The arrows on the left side represent monomeric and dimeric forms of MSR. This experiment is representative of three similar experiments.



To dissect the molecular mechanisms by which TNF-alpha suppressed macrophage scavenger receptor protein expression, we initially examined the influence of TNF-alpha on macrophage scavenger receptor mRNA levels. Northern blot analyses of PMA-differentiated THP-1 macrophages revealed a time-dependent increase in macrophage scavenger receptor mRNA steady state levels in response to PMA (Fig. 4, A and B). Expression peaked at 48 h. Macrophage scavenger receptor mRNA was not detected in undifferentiated THP-1 monocytes (not treated with PMA), and TNF-alpha had no effect on this baseline expression. TNF-alpha decreased macrophage scavenger receptor mRNA expression by 80 (at 20 h) and 70% (at 48 h), respectively, in PMA-differentiated cells relative to PMA-differentiated cells not treated with TNF-alpha (THP-1 macrophages) (Fig. 4, A and B). RT-PCR demonstrated that TNF-alpha decreased both human macrophage scavenger receptor types SR-AI and SR-AII mRNA in PMA-treated THP-1 macrophages (Fig. 4C). Dose response experiments showed that maximal inhibition of macrophage scavenger receptor mRNA levels (similar to macrophage scavenger receptor surface expression as determined by aLDL binding) by TNF-alpha occurred at 200 units/ml (data not shown).


Figure 4: TNF-alpha decreases MSR mRNA synthesis in PMA-differentiated THP-1 macrophages at steady state level. A, total RNA was isolated from THP-1 cells grown in serum-free medium (Control, THP-1 monocytes, samples 1 and 5), medium containing PMA (150 nM) (PMA, THP-1 macrophages, samples 2 and 6), medium containing PMA (150 nM) + TNF-alpha (200 units/ml) (PMA + TNF-alpha, samples 3 and 7), or medium containing TNF-alpha (200 units/ml) (TNF-alpha, samples 4 and 8) for 20 and 48 h, respectively. Northern blots were hybridized with P-labeled cDNAs of MSR or 28 S. The respective autoradiograms with MSR and 28 S bands are labeled and indicated with arrows. B, histograms represent quantification by PhosphorImager® of MSR mRNA normalized by comparison with 28 S ribosomal RNA. All data are expressed as a percentage of sample 2, i.e. PMA-differentiated THP-1 macrophages. Similar results were obtained in three separate experiments. C, RT-PCR analysis of the expression of macrophage scavenger receptor types SR-AI and SR-AII mRNA in THP-1 monocytes, PMA-differentiated THP-1 macrophages in the absence and the presence of TNF-alpha. Ethidium bromide-stained agarose gel with MSR type SR-AI at 447 base pairs and MSR type SR-AII at about 285 base pairs. Lane 1, 100 base pair DNA ladder; lane 2, THP-1 monocytes; lane 3, PMA-differentiated THP-1 macrophages (24 h); lane 4, THP-1 cells with PMA + TNF-alpha (24 h); lane 5, DNA molecular weight marker V from Boehringer Mannheim. The detailed method is described under ``Experimental Procedures.'' There was no detectable MSR type SR-AI and SR-AII mRNA in THP-1 cells with TNF-alpha (data not shown). The arrows indicate MSR types SR-AI and SR-AII. The results shown are representative of three independent experiments.



To examine if decreased macrophage scavenger receptor mRNA expression in response to TNF-alpha in PMA-differentiated THP-1 macrophages resulted from decreased transcription of the macrophage scavenger receptor gene, assays for luciferase activity driven by macrophage scavenger receptor gene promoter were performed. THP-1 cells were transiently transfected by the DEAE-dextran sulfate method with plasmid MSR-Luc luciferase construct consisting of 5` upstream sequences of the macrophage scavenger receptor promoter region. Luciferase activity was measured in untreated cells, cells treated with PMA, and cells treated with PMA + TNF-alpha (200 units/ml). PMA induced luciferase activity driven by the macrophage scavenger receptor gene promoter by 3.5-fold. TNF-alpha reduced luciferase activity by 20% after 12 h (Fig. 5).


Figure 5: TNF-alpha down-regulates MSR gene transcriptional activity in PMA-differentiated THP-1 macrophages. THP-1 cells were transfected by the DEAE-dextran sulfate method with plasmid MSR-Luc luciferase construct consisting of 5` upstream sequences of the promoter region from MSR gene of THP-1 macrophages (e.g. plasmids HACLDL Xba-A1-luc promoter or HACLDL Xba-A1-luc Enhancer) or control plasmid and co-transfected with beta-galactosidase. After 24 h post-transfection, cells were treated with PMA (150 nM) or PMA (150 nM) + TNF-alpha (200 units/ml). The luciferase activities of transfected cells were measured at the indicated time. The data are expressed as the means of quadruplicate samples ± S.E. (p leq 0.05) and are representative of three separate experiments..



To determine if TNF-alpha reduced the level of macrophage scavenger receptor mRNA by increasing its rate of degradation, we measured the half-life of macrophage scavenger receptor mRNA in the presence of the transcription inhibitor actinomycin D (5 µg/ml). TNF-alpha shortened the half-life of macrophage scavenger receptor mRNA from 40 ± 3 to 10 ± 2 h (Fig. 6, A, B, and C). Therefore, the reduction in macrophage scavenger receptor message by TNF-alpha appears to be mediated principally by a post-transcriptional mechanism, namely, accelerating the degradation of macrophage scavenger receptor mRNA. Moreover, incubation of cells with the protein synthesis inhibitor cycloheximide (10 µg/ml) prevented the decrease of macrophage scavenger receptor mRNA at both 3 and 6 h in TNF-alpha-treated samples (Fig. 7). These findings suggest that the effect(s) of TNF-alpha on macrophage scavenger receptor mRNA destabilization requires new protein synthesis.


Figure 6: Northern blots showing the effects of TNF-alpha on the half-life of MSR mRNA in the presence actinomycin D. Human THP-1 monocytes were treated with PMA (150 nM) + TNF-alpha (200 units/ml) (A) or PMA (150 nM) alone (B) for 24 h before addition of actinomycin D (5 µg/ml). Total RNA was harvested at the indicated times and analyzed by Northern blotting with P-labeled probes of MSR and 28 S. C, mRNA in A and B were quantitated using a PhosphorImager® and normalized by comparison of 28 S RNA. Northern blot analyses shows MSR mRNA levels (relative intensity compared with control sample at t = 0 h) as a semi-log function of time in the presence of actinomycin D alone or in the combination with TNF-alpha. The experiments were performed two times.




Figure 7: Northern blots showing reversal by cycloheximide of the destabilizing effects of TNF-alpha on MSR mRNA. PMA-differentiated THP-1 macrophages were treated with cycloheximide (10 µg/ml) for 1 h before the addition of TNF-alpha (200 units/ml). PMA-differentiated THP-1 macrophages (PMA (Control)), PMA-differentiated THP-1 macrophages treated with TNF-alpha (PMA + TNF-alpha), and PMA-differentiated THP-1 macrophages treated with TNF-alpha and incubated with cycloheximide (PMA + TNF-alpha + CHX) were harvested 3 and 6 h after exposure to TNF-alpha. Northern blots were hybridized with P-labeled cDNAs of MSR and 28 S ribosomal RNA, quantitated by PhosphorImager®, and normalized by comparison with 28 S. All of the data are expressed as a percentage relative to THP-1 macrophages (t = 3 h). The relative intensity of MSR mRNA is plotted against time. Pretreating THP-1 macrophages for 1 h with cycloheximide had no effect on the basal level of MSR mRNA (data not shown). Similar results were obtained in three separate experiments.



Lastly, we characterized the role of TNF-alpha in macrophage scavenger receptor-mediated CE metabolism by evaluating parameters of the CE cycle. ACAT activity (Fig. 8A) as well as esterification of free cholesterol with [^3H]oleic acid to CE (Fig. 8B) were evaluated in PMA-differentiated THP-1 macrophages and PMA-differentiated THP-1 cells treated with TNF-alpha. TNF-alpha caused a significant (65%) reduction in ACAT activity and a similar decrease in the synthesis of nascent CE from free fatty acids as compared with untreated cells. These decreases paralleled the decrease in aLDL binding and most likely reflect a decrease in cholesterol delivery. Finally, the effects of TNF-alpha on CE hydrolase activities were measured, but no significant difference in acid CE hydrolase or neutral CE hydrolase activities in response to TNF-alpha was observed (data not shown).


Figure 8: A, effect of TNF-alpha on ACAT activity in PMA-differentiated THP-1 macrophages. PMA-differentiated THP-1 macrophages were co-incubated with TNF-alpha (200 units/ml for 12 and 24 h) and homogenized after washing with ice-cold phosphate-buffered saline. Homogenates were assayed for ACAT activity as described under ``Experimental Procedures.'' All of the data derived from the group of THP-1 macrophages treated with TNF-alpha (asterisks) are significantly (p < 0.05) different from the group of THP-1 macrophages. The data represent the means of quadruplicate wells ± S.E. This figure is representative of three such experiments. B, esterification of cholesterol is decreased in TNF-alpha-treated PMA-differentiated THP-1 macrophages. Esterification of cholesterol was performed as described under ``Experimental Procedures.'' Cell lipids were extracted, and radioactivity in cellular CE was measured after separation by thin layer chromatography. All data derived from the group of THP-1 macrophages treated with TNF-alpha (asterisks) are significantly (p < 0.05) different from the group of THP-1 macrophages. The data represent the means of quadruplicate wells ± S.E. This figure is representative of three such experiments.




DISCUSSION

Expression of the macrophage scavenger receptor (acetylated LDL receptor) occurs as monocytes differentiate into macrophages in tissue culture over a period of several days, a process that mimics what is thought to occur as blood monocytes enter tissue to become tissue macrophages. These differentiation events can be mimicked by treating monocytes or some (but not all) monocytic cell lines, such as THP-1 cells, with PMA. PMA activates protein kinase C (8, 38) in THP-1 cells concomitantly with the differentiation of this cell type into macrophage-like cells(7, 17, 18) .

Fogelman and his colleagues had previously shown that LPS inhibited scavenger receptor activity in human macrophages (13) and that this inhibitory effect could be blocked with an antibody to TNF-alpha(1) . We utilized PMA-differentiated THP-1 macrophages to evaluate the molecular mechanisms by which TNF-alpha inhibited macrophage scavenger receptor expression. The inhibitory effect of TNF-alpha on macrophage scavenger receptor expression and activity is comparable with previously demonstrated inhibitory effects of IFN- and TGF-beta1 on the macrophage scavenger receptor. TNF-alpha inhibited macrophage scavenger receptor activity (aLDL binding, Fig. 1), protein synthesis (Fig. 3), and mRNA steady state levels (Fig. 4). TNF-alpha caused a 6-fold decrease in macrophage scavenger receptor number without affecting receptor affinity in PMA-differentiated THP-1 macrophages. IFN- inhibited macrophage scavenger receptor activity in human (5) or mouse monocyte-derived macrophages(6) . IFN- inhibited binding, internalization, and degradation of aLDL and reduced macrophage scavenger receptor mRNA steady state levels in comparison with untreated cells. This resulted in a reduction of cholesterol and CE content. Inhibition of binding resulted from decreased numbers of aLDL binding sites without a significant change in receptor affinity. Similarly, TGF-beta1 inhibited macrophage scavenger receptor activity and mRNA in PMA-differentiated THP-1 macrophages (7) and caused a decrease in binding of aLDL, degradation of aLDL, and ACAT activity relative to PMA-differentiated THP-1 cells. TGF-beta1 caused a 2-fold decrease in macrophage scavenger receptor number as well as a decrease in receptor affinity.

Inhibition of macrophage scavenger receptor expression in response to cytokines is cell-specific. TNF-alpha and IFN- increased scavenger receptor activity and mRNA in rabbit vascular smooth muscle cells (39) . TGF-beta, in combination with other cytokines, increased scavenger receptor activity in rabbit smooth muscle cells(40) . The mechanism for the divergent effects of these cytokines on these two cell types (macrophages and smooth muscle cells) is unknown. However, it may reflect the fact that basal level of scavenger receptor expression in these two cell types is markedly different. Macrophages constitutively express macrophage scavenger receptor, whereas smooth muscle cells express little or no scavenger receptor mRNA or protein unless induced by cytokines, growth factors, or PMA(39, 40) . (^2)

Macrophage scavenger receptor mRNA steady state levels in THP-1 monocytes were up-regulated by the addition of PMA; however, TNF-alpha decreased macrophage scavenger receptor mRNA steady state levels to about 30% of THP-1 macrophages (Fig. 4, A and B). Two isoforms of macrophage scavenger receptor, types SR-AI and SR-AII, on human macrophages (including PMA-differentiated THP-1 macrophages) are encoded by a single gene that gives rise to an alternatively spliced primary transcript(41, 42, 43) . To further determine the effect of TNF-alpha on the differential expression of the macrophage scavenger receptor gene subtypes, RT-PCR amplification for human macrophage scavenger receptor types SR-AI and SR-AII in PMA-differentiated THP-1 macrophages was performed. We found that TNF-alpha destabilizes the expression of both macrophage scavenger receptor isoforms (SR-AI and SR-AII) during the differentiation of THP-1 monocytes to THP-1 macrophages (Fig. 4C).

Glass and his colleagues have studied transcriptional regulation of the macrophage scavenger receptor gene in PMA-differentiated THP-1 macrophages(8, 28, 44) . They have identified transcription factor binding sites for AP-1, SP-1, and ets in the promoter of macrophage scavenger receptor gene from THP-1 macrophages(8) . Furthermore, the mechanisms for developmental regulation and cell-specific expression of macrophage scavenger receptor gene have been investigated. Complicated growth- and differentiation-related regulatory pathways of macrophage scavenger receptor gene transcription in THP-1 macrophages have been proposed(28, 44) . Specifically, positive transcriptional control of the macrophage scavenger receptor is dependent on the combinatorial interactions of multiple positive factors (including Spi-1/PU.1, which binds to the region I, and a ternary complex of c-Jun, JunB, and an ets2-like protein, which binds to the region IV) and negative factors (undefined inhibitory elements, which bind to the regions II, III and VI)(44) . Moreover, the ternary complex binding to the region IV is a target for transcriptional activation following stimulation of THP-1 monocytes with PMA.

Decreased expression of macrophage scavenger receptor mRNA in response to TNF-alpha resulted, in part, from decreased transcriptional activity of macrophage scavenger receptor gene. Specifically, PMA increased macrophage scavenger receptor mRNA in THP-1 monocytes via the transcriptional activation of the macrophage scavenger receptor gene as shown (Fig. 5) and as described(44) . TNF-alpha reduced macrophage scavenger receptor gene transcription by 20% (Fig. 5). TNF-alpha has been show to decrease the transcriptional rate of many genes(45, 46, 47) . However, other genes are induced in response to TNF-alpha mediated by the induction of transcription factors such as NFkappaB, AP-1, IRF-1, and NF-GMa(48) . Whether the effect of TNF-alpha on transcriptional down-regulation of macrophage scavenger receptor mRNA alters the combinatorial interactions of positive and negative factors as described (44) remains to be further investigated.

Our results demonstrate that in the presence of actinomycin D (an inhibitor of transcription), TNF-alpha inhibited macrophage scavenger receptor mRNA principally by reducing macrophage scavenger receptor mRNA half-life (Fig. 6). Although both IFN- (5, 6) and TGF-beta1 (7) inhibited macrophage scavenger receptor mRNA steady state levels, it was undetermined if these cytokines reduced macrophage scavenger receptor transcription or if the reduction in mRNA steady state levels was due to increased mRNA degradation. The TNF-alpha reduction in macrophage scavenger receptor mRNA half-life was inhibited by cycloheximide, implying that new protein synthesis was necessary and suggesting that TNF-alpha induced expression of protein(s) that accelerated macrophage scavenger receptor mRNA degradation (Fig. 7). A reduction of endothelial cell nitric oxide synthase mRNA half-life has also been demonstrated in response to TNF-alpha (49, 50, 51) and was dependent on protein synthesis(49) .

To assess the effects of TNF-alpha on cholesterol trafficking in THP-1 macrophages, the role of TNF-alpha in macrophage scavenger receptor-mediated CE metabolism was characterized by evaluating parameters in the CE cycle. TNF-alpha decreased ACAT activity (Fig. 8A) and esterification of free cholesterol (Fig. 8B) by 65% as compared with untreated cells and paralleled the decrease in aLDL binding. Decreased ACAT activity most likely resulted from decreased substrate (e.g. cholesterol) availability to the enzyme. However, we cannot rule out the possibility that decreased ACAT activity in response to TNF-alpha may occur through phosphorylation of ACAT by protein kinase(52) . CE hydrolytic enzymes such as acid CE hydrolase and neutral CE hydrolase activities were unaffected by TNF-alpha treatment.

These findings may have physiologic significance in the pathogenesis of atherosclerosis. Scavenger receptors are expressed by macrophages in atherosclerotic lesions and are believed to mediate the binding and uptake of modified LDL including oxidized LDL. Cytokines produced by cells comprising the atheroma (macrophages, endothelial cells, smooth muscle cells, and lymphocytes) modulate macrophage scavenger receptor expression in vitro and are thought to participate in modulating expression in vivo. The expression of TNF-alpha is increased in atherosclerotic tissue (53, 54) in comparison with normal vascular tissue. TNF-alpha within the atherosclerotic lesion could have a modulatory or inhibitory effect on macrophage scavenger receptor-mediated accumulation of oxidized lipoprotein by macrophages. We have previously demonstrated that TNF-alpha can up-regulate expression of the LDL receptor by HepG2 cells (55) by increasing LDL receptor gene transcription. This study and our previous work (55) demonstrate how cytokines can modulate transcriptional and post-transcriptional regulation of lipoprotein receptors. These regulatory effects may potentially alter lipoprotein metabolism in vascular and hepatic tissues and alter pathophysiologic processes.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants HL-49666 and HL-46403. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Recipient of National Institutes of Health School Faculty Development Award K14 HL-03158.

Recipient of National Institutes of Health Research Scientist Development Award K01 RR-00085.

**
To whom correspondence should be addressed: Dept. of Biochemistry, Cornell University Medical College, 1300 York Ave., New York, NY 10021. Tel.: 212-746-6470; Fax: 212-746-8789.

(^1)
The abbreviations used are: LDL, low density lipoprotein; MSR, macrophage scavenger receptor; aLDL, acetylated LDL; LPS, lipopolysaccharide; TNF-alpha, tumor necrosis factor-alpha; M-CSF, macrophage colony-stimulating factor; RT, reverse transcription; PCR, polymerase chain reaction; CE, cholesteryl ester; ACAT, acyl CoA:cholesterol acyltransferase; PMA, phorbol 12-myristate 13-acetate; IFN-; interferon-; TGF-beta1, transforming growth factor-beta1.

(^2)
H.-Y. Hsu, A. C. Nicholson, and D. P. Hajjar, unpublished data.


ACKNOWLEDGEMENTS

We thank Terrance Win for technical assistance.


REFERENCES

  1. van Lenten, B. J., and Fogelman, A. M. (1992) J. Immunol. 148, 112-116 [Abstract/Free Full Text]
  2. Goldstein, J. L., Ho, Y. K., Basu, S. K., and Brown, M. S. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 333-337 [Abstract]
  3. Via, D. P., Pons, L., Dennison, D. K., Fanslow, A. E., and Bernini, F. (1989) J. Lipid Res. 30, 1515-1524 [Abstract]
  4. Ishibashi, S., Inaba, T., Shimano, H., Harada, K., Inoue, I., Mokuno, H., Mori, N., Gotoha, T., Takaku, F., and Yamada, N. (1990) J. Biol. Chem. 265, 14109-14117 [Abstract/Free Full Text]
  5. Fong, L., Fong, A., and Cooper, A. (1990) J. Biol. Chem. 265, 11751-11760 [Abstract/Free Full Text]
  6. Geng, Y.-J., and Hansson, G. K. (1992) J. Clin. Invest. 89, 1322-1330 [Medline] [Order article via Infotrieve]
  7. Bottalico, L. A., Wager, R. E., Agellon, L. B., Assoian, R. K., and Tabas, I. (1991) J. Biol. Chem. 266, 22866-22871 [Abstract/Free Full Text]
  8. Moulton, K. S., Wu, H., Barnett, J., Parthasarathy, S., and Glass, C. K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8102-8106 [Abstract]
  9. Philips, D. R., Arnold, K., and Innerarity, T. L. (1985) Nature 316, 746-748 [Medline] [Order article via Infotrieve]
  10. Aviram, M. (1989) Metabolism 38, 425-430 [Medline] [Order article via Infotrieve]
  11. Aviram, M., Dankner, G., and Brook, J. G. (1990) Arteriosclerosis 10, 559-563 [Abstract]
  12. Fogelman, A. M., Seager, J., Haberland, M. E., Hokom, M., Tanaka, R., and Edward, P. A. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 922-926 [Abstract]
  13. van Lenten, B. J., Fogelman, A. M., Seager, J., Ribi, E., Haberland, M., and Edwards, P. (1985) J . Immunol. 134, 3718-3721 [Abstract/Free Full Text]
  14. Naito, M., Suzuki, H., Mori, T., Matsumoto, A., Kodama, T., and Takahashi, K. (1992) Am. J. Pathol. 141, 591-599 [Abstract]
  15. Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., and Tada, K. (1980) Int. J. Cancer 26, 171-176 [Medline] [Order article via Infotrieve]
  16. Tsuchiya, S., Kobayashi, Y., Goto, Y., Okumura, H., Nakae, S., Konno, T., and Tada, K. (1982) Cancer Res. 42, 1530-1536 [Abstract]
  17. Hara, H., Tanishita, H., Yokoyama, S., Tajima, S., and Yamamoto, A. (1987) Biochem. Biophys. Res. Commun. 146, 802-808 [Medline] [Order article via Infotrieve]
  18. Kodama, T., Freeman, M., Rohrer, L., Zabrecky, J., Matsudaira, P., and Krieger, M. (1990) Nature 343, 531-535 [CrossRef][Medline] [Order article via Infotrieve]
  19. Hajjar, D. P., Falcone, D. J., Fabricant, C. G., and Fabricant, J. (1985) J. Biol. Chem. 260, 6124-6128 [Abstract/Free Full Text]
  20. Marshall, P., Warso, M., and Lands, W. (1985) Anal. Biochem. 145, 192-199 [Medline] [Order article via Infotrieve]
  21. Bilheimer, D., Eisenberg, S., and Levy, R. (1972) Biochim. Biophys. Acta 260, 212-221 [Medline] [Order article via Infotrieve]
  22. Goldstein, J., Basu, S., and Brown, M. (1983) Methods Enzymol. 98, 241-260 [Medline] [Order article via Infotrieve]
  23. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5894-5898
  24. Davis, L., Dibner, M., and Battery, J. (1986) Basic Methods in Molecular Biology , pp. 130-146, Elsevier Science Publishing Co., Inc., New York
  25. Hsu, H.-Y., Nicholson, A. C., and Hajjar, D. P. (1994) J. Biol. Chem. 269, 9213-9220 [Abstract/Free Full Text]
  26. Matsumoto, A., Naito, M., Itakura, H., Ikemoto, S., Asaoka, H., Hayakawa, I., Kanamori, H., Aburatani, H., Takaku, F., Suzuki, H., Kobari, Y., Miyai, T., Takahashi, K., Cohen, E. H., Wydro, R., Housman, D. E., and Kodama, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9133-9137 [Abstract]
  27. Dorsett, D. L., Keshet, I., and Winocour, E. (1983) J. Virol. 48, 218-228 [Medline] [Order article via Infotrieve]
  28. Wu, H., Moulton, K., Horvai, A., Parik, S., and Glass, C. K. (1994) Mol. Cell. Biol. 14, 2129-2139 [Abstract]
  29. Haley, N. J., Fowler, S., and deDuve, C. (1980) J. Lipid Res. 21, 961-969 [Medline] [Order article via Infotrieve]
  30. Hajjar, D. P., and Weksler, B. (1983) J. Lipid Res. 24, 1176-1185 [Abstract]
  31. Hajjar, D. P., Weksler, B. B., Falcone, D. J., Hefton, J. H., Tack-Goldman, K., and Minick, C. R. (1982) J. Clin. Invest. 70, 479-488 [Medline] [Order article via Infotrieve]
  32. Hajjar, D. P., Wight, T., and Smith, S. (1980) Am. J. Pathol. 100, 683-705 [Medline] [Order article via Infotrieve]
  33. Margolis, B., Rhee, S. G., Felder, S., Mervic, M., Lyall, R., Levitzki, A., Ullrich, A., Zilberstein, A., and Schlessinger, J. (1989) Cell 57, 1101-1107 [Medline] [Order article via Infotrieve]
  34. Laemmli, U. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  35. Geng, Y.-J., Kodama, T., and Hansson, G. K. (1994) Arterioscler. Thromb. 14, 798-806 [Abstract]
  36. Villiers, W. J. S. D., Fraser, I. P., Hughes, D. A., Doyle, A. G., and Gordon, S. (1994) J. Exp. Med. 180, 705-709 [Abstract]
  37. Lowry, O., Rosebrough, N., Farr, A., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  38. Akeson, A. L., Schroeder, K., Woods, C., Schmidt, C. J., and Jones, W. D. (1991) J. Lipid Res. 32, 1699-1707 [Abstract]
  39. Li, H.-M., Freeman, M., and Libby, P. (1995) J. Clin. Invest. 95, 122-133 [Medline] [Order article via Infotrieve]
  40. Gong, Q., and Pitas, R. E. (1995) J. Biol. Chem. 270, 21672-21678 [Abstract/Free Full Text]
  41. Freeman, M., Ashkenas, J., Rees, D. J., Kingsley, D. M., Copeland, N. G., Jenkins, N. A., and Krieger, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8810-8814 [Abstract]
  42. Emi, M., Asaoka, A., Matsumoto, A., Itakura, H., Kurihara, Y., Wada, Y., Kanamori, H., Yazaki, Y., Takahashi, E., Lepert, M., Lalouel, J.-M., Kodama, T., and Mukai, T. (1993) J. Biol. Chem. 268, 2120-2125 [Abstract/Free Full Text]
  43. Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637 [CrossRef][Medline] [Order article via Infotrieve]
  44. Moulton, K. S., Semple, K., Wu, H., and Glass, C. K. (1994) Mol. Cell. Biol. 14, 4408-4418 [Abstract]
  45. Solis-Herruzo, J. A., Brenner, D. A., and Chojkier, M. (1988) J. Biol. Chem. 263, 5841-5845 [Abstract/Free Full Text]
  46. Conway, E. M., and Rosenberg, R. D. (1988) Mol. Cell. Biol. 8, 5588-5592 [Medline] [Order article via Infotrieve]
  47. Pape, M. E., and Kim, K.-H. (1989) Mol. Cell. Biol. 9, 974-982 [Medline] [Order article via Infotrieve]
  48. Schutze, S., Machleidt, T., and Kronke, M. (1992) Semin. Oncol. 19, 16-24 [Medline] [Order article via Infotrieve]
  49. Yoshizumi, Y., Perrella, M. A., Burnett, J. C., and Lee, M.-E. (1993) Circ. Res. 73, 205-209 [Abstract]
  50. Mohamed, F., Monge, J. C., Gordan, A., Cernacek, P., Blais, D., and Stewart, D. J. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 52-57 [Abstract/Free Full Text]
  51. Mohamed, F., Monge, J. C., Lukose, A., Farshadi, F., Cernacek, P., and Stewart, D. J. (1995) FASEB J. 9, 326 (Abstr. 1890)
  52. Corton, J. M., and Hardie, D. G. (1992) Eur. J. Biochem. 204, 203-208 [Abstract]
  53. Rus, H. G., Niculescu, F., and Vlaicu, R. (1991) Atherosclerosis 89, 247-254 [Medline] [Order article via Infotrieve]
  54. Tipping, P. G., and Hancock, W. W. (1993) Am. J. Pathol. 142, 1721-1728 [Abstract]
  55. Stopeck, A. T., Nicholson, A. C., Mancini, F. P., and Hajjar, D. P. (1993) J. Biol. Chem. 268, 17489-17494 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.